摘要
目的探讨肝细胞癌(HCC)患者术前血浆纤维蛋白原(FIB)、D-二聚体(DD)与临床病理特征的相关性。方法收集2015年9月至2017年10月在昆明医科大学第二附属医院接受手术治疗的178例HCC患者的临床病例资料,对其术前血浆FIB、DD水平与临床病理特征进行单因素和Logistic回归多因素分析。结果单因素分析结果显示血浆高FIB水平(>4.00g/L)与男性、高白细胞、高血小板、高血清清蛋白、最大肿瘤直径、肝硬化、脾大、Ki-67高表达均相关(P<0.05),血浆高DD水平(>0.55μg/mL)与男性、高白细胞、高血小板、最大肿瘤直径、淋巴转移、高级别病理分级、CK19(+)、Ki-67高表达均相关(P<0.05)。Logistic回归多因素分析结果显示:高白细胞(OR=1.618,95%CI:1.03~2.54,P=0.037)、最大肿瘤直径(OR=1.421,95%CI:1.10~1.84,P=0.008)与血浆高FIB水平(>4.00g/L)相关,最大肿瘤直径(OR=1.324,95%CI:1.05~1.67,P=0.019)与血浆高DD水平(>0.55μg/mL)相关。结论高FIB及高DD水平可影响HCC患者预后,可采用抗凝疗法可改善患者预后。
Objective To investigate the correlation between preoperative plasma fibrinogen(FIB)and D-dimer(DD)with clinicopathological features in the patients with hepatocellular carcinoma(HCC).Methods The clinical data of 178 patients with HCC treated by operation in the Second Affiliated Hospital of Kunming Medical University from September 2015 to October 2017 were collected.The correlation between preoperative plasma FIB and DD levels with clinicopathologic features was analysed by using the univariate and Logistic regression multivariate analysis.Results The univariate analysis results showed that high plasma FIB(>4.00 g/L)was correlated with male,high WBC,high platelet,high serum albumin,maximal tumor diameter,liver cirrhosis,splenomegaly and Ki-67 high expression(P<0.05);plasma high DD level(>0.55μg/mL)was correlated with male,high WBC,high platelet,maximal tumor diameter,lymphatic metastasis,high grade pathological stage,CK19(+)and Ki-67 high expression(P<0.05).The Logistic regression analysis results showed that high WBC(OR=1.618,95%CI:1.03-2.54,P=0.037)and maximal tumor diameter(OR=1.421,95%CI:1.10-1.84,P=0.008)were correlated with high plasma FIB level(>4.00 g/L),and the maximal tumor diameter(OR=1.324,95%CI:1.05-1.67,P=0.019)was correlated with plasma high DD level(>0.55μg/mL).Conclusion High FIB and high DD may affect the prognosis of the patients with HCC,and anticoagulant therapy can improve the prognosis of the patients.
作者
郭志唐
邹仁超
柯阳
戈佳云
鲍天昊
雷学芬
陈浩天
王琳
GUO Zhitang;ZOU Renchao;KE Yang;GE Jiayun;BAO Tianhao;LEI Xuefen;CHEN Haotian;WANG Lin(Department of Hepatobiliary Surgery,Second Affiliated Hospital of Kunming Medical University,Kunming Yunnan 650101,China;Department of Oncology, Second Affiliated Hospital of Kunming Medical University,Kunming Yunnan 650101,China)
出处
《重庆医学》
CAS
2019年第13期2210-2216,共7页
Chongqing medicine
基金
国家自然科学基金项目(81660399)
云南省卫生健康委员会领军人才培养计划项目(L-201622)
昆明医科大学第二附属医院肝胆外科省创新团队项目(2015HC033)
